Physician profile
Carl Shultz
NPI 1912351826
$1,386.30
in general payments reported to CMS, 2019-2025
9 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.00 · 2020: $75.00 · 2021: $413 · 2022: $99.95 · 2023: $130 · 2024: $391 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $586.26 | 2021-2025 | |
| Celgene Corporation | $314.24 | 2023-2025 | Abecma, Breyanzi, Reblozyl |
| Incyte Corporation | $198.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $89.90 | 2024 | Abecma |
| Amgen INC. | $75.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $71.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.51 | 2025 | |
| Daiichi Sankyo INC. | $19.44 | 2025 | Vanflyta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.